A Study of the Immune Response to Heplisav in Healthy Older Adults
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 50 - 70 |
| Updated: | 3/22/2019 |
| Start Date: | November 2013 |
| End Date: | March 2015 |
A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.
This study will investigate the response of the immune system to a hepatitis B (HB) vaccine
in healthy adults 50 to 70 years of age. This study is partially funded by the National
Institute of Allergy and Infectious Diseases.
in healthy adults 50 to 70 years of age. This study is partially funded by the National
Institute of Allergy and Infectious Diseases.
The purpose of this study is to examine how the immune system responds to vaccination with
HEPLISAV.
HEPLISAV.
Inclusion Criteria:
- 50 to 70 years of age, inclusive
- In good health in the opinion of the principal investigator, based upon medical
history and physical examination
- Serum negative for HBsAg, anti-HBs, antibody to hepatitis B core antigen (anti-HBc),
hepatitis C virus (HCV), and human immunodeficiency virus (HIV)
- If female of childbearing potential, agree to consistently use a highly effective
method of birth control from the screening visit through Week 12/Visit 10
Exclusion Criteria:
- Pregnant, breastfeeding, or planning a pregnancy
- Known history of an autoimmune disease
- Previously received any hepatitis B vaccine (approved or investigational)
- Body-mass index (BMI) >30 kg/m2, diabetes mellitus (type 1 or 2), or other chronic
medical condition that in the opinion of the principal investigator might interfere
with the immune response to hepatitis B vaccination
We found this trial at
1
site
Click here to add this to my saved trials
